There are myriad targets that have been deemed undruggable and they "have rankled even the best-funded laboratories over the years," The Scientist says. However, some biotechs are game for taking those impossible targets on — and they appear to be seeing some success. The Scientist notes that one of those companies, Anchor Therapeutics, is working on targeting membrane receptors for Novartis and Ortho-McNeil-Janssen Pharmaceuticals.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.

Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.

Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.

In Nature this week: sequenced genomes of five additional Neanderthals, and more.